PrEP on Twitter: Information, Barriers, and Stigma.
On May 14, 2014 the Centers for Disease Control and Prevention (CDC) endorsed the drug Truvada as an HIV preventative, called pre-exposure prophylaxis (PrEP). PrEP has been shown to dramatically reduce the risk of HIV infection, but its rate of adoption has been slow, and discourse surrounding it has been marked by stigma and uncertainty. The purpose of this study was to investigate how PrEP was discussed on Twitter. Our analysis focused on barriers to PrEP adoption and stigmatization of PrEP users. We analyzed a random sample of 1,093 top tweets about PrEP posted to Twitter a year before and a year after the CDC's endorsement. Our results showed that tweets likely reinforced uncertainty about barriers to PrEP adoption and that users employed Twitter's functionality to counter stigmatizing narratives about PrEP. We suggest that our findings illuminate both the limitations and strengths of Twitter as a mechanism for health promotion.
a Department of Communication Studies , Northeastern University.
Joseph
J
Schwartz
b Manship School of Mass Communication , Louisiana State University.
Josh
J
Grimm
D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination / Q000191:economics / Q000627:therapeutic use*; D015658:HIV Infections / Q000517:prevention & control* / Q000523:psychology*; D007722:Health Knowledge, Attitudes, Practice; D006297:Health Services Accessibility; D006801:Humans; D065129:Pre-Exposure Prophylaxis / Q000191:economics / Q000379:methods*; D061108:Social Media; D057545:Social Stigma; D016312:Treatment Refusal
D000069480:Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination